Search

Your search keyword '"Sampaio-Barros, Percival D."' showing total 18 results
Start Over Author "Sampaio-Barros, Percival D." Publication Year Range Last 3 years
18 results on '"Sampaio-Barros, Percival D."'

1. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis

Author

Bautista-Molano, Wilson, Fernández-Ávila, Daniel G., Brance, María Lorena, Ávila Pedretti, María Gabriela, Burgos-Vargas, Ruben, Corbacho, Inés, Cosentino, Vanesa Laura, Díaz Coto, José Francisco, Giraldo Ho, Enrique, Gomes Resende, Gustavo, Gutiérrez, Luis Arturo, Gutiérrez, Marwin, Ibáñez Vodnizza, Sebastián Eduardo, Jáuregui, Edwin, Ocampo, Vanessa, Palleiro Rivero, Daniel Ruben, Palominos, Penélope Esther, Pacheco Tena, Cesar, Quiceno, Guillermo Andrés, Saldarriaga-Rivera, Lina María, Sommerfleck, Fernando Andrés, Goecke Sariego, Annelise, Vera Barrezueta, Claudia, Vega Espinoza, Luis Enrique, Vega Hinojosa, Oscar, Citera, Gustavo, Lozada, Carlos, Sampaio-Barros, Percival D., Schneeberger, Emilce, and Soriano, Enrique R.

Published
2023
Full Text
View/download PDF

2. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

Author

Matucci Cerinic, Marco, Walker, Ulrich, Iannone, Florenzo, Jordan, Suzana, Becvar, Radim, Kowal Bielecka, Otylia, Cutolo, Maurizio, Cuomo, Giovanna, Kedor, Claudia, Rednic, Simona, Avouac, Jérome, Vlachoyiannopoulos, P., Montecucco, C., Stork, Jiri, Inanc, Murat, Carreira, Patricia E., Novak, Srdan, Czirják, László, Iudici, Michele, Kucharz, Eugene J., Zanatta, Elisabetta, Perdan-Pirkmajer, Katja, Coleiro, Bernard, Moroncini, Gianluca, Farge Bancel, Dominique, Airò, Paolo, Hesselstrand, Roger, Radic, Mislav, Braun-Moscovici, Yolanda, Lo Monaco, Andrea, Hunzelmann, Nicolas, Pellerito, Raffaele, Giollo, Alessandro, Morovic-Vergles, Jadranka, Denton, Christopher, Vonk, Madelon, Damjanov, Nemanja, Henes, Jörg, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Hasler, Paul, Kohm, Michaela, Foeldvari, Ivan, Bajocchi, Gianluigi, Salvador, Maria João, Stamenkovic, Bojana, Selmi, Carlo Francesco, Tikly, Mohammed, Ananieva, Lidia P., Herrick, Ariane, Müller-Ladner, Ulf, De Palma, Raffaele, Engelhart, Merete, Szücs, Gabriela, Sobrino Grande, Cristina, Midtvedt, Øyvind, Launay, David, Riccieri, Valeria, Ionescu, Ruxandra Maria, Sha, Ami, Gheorghiu, Ana Maria, Sunderkötter, Cord, Ingegnoli, Francesca, Mouthon, Luc, Smith, Vanessa, Cantatore, Francesco Paolo, Ullman, Susanne, Alberto von Mühlen, Carlos, Pozzi, Maria Rosa, Eyerich, Kilian, Wiland, Piotr, Vanthuyne, Marie, Alegre-Sancho, Juan Jose, Herrmann, Kristine, De Langhe, Ellen, Anic, Branimir, Üprus, Maria, Yavuz, Sule, Granel, Brigitte, de Souza Müller, Carolina, Busquets, Joanna, Agachi, Svetlana, Stebbings, Simon, Mathieu, D'Alessandro, Sampaio-Barros, Percival D., Stamp, Lisa, Solanki, Kamal, Veale, Douglas, Loyo, Esthela, Li, Mengtao, Abdel Atty Mohamed, Walid Ahmed, Gigante, Antonietta, Oksel, Fahrettin, Tanaseanu, Cristina-Mihaela, Foti, Rosario, Ancuta, Codrina, Maurer, Britta, van Laar, Jacob, Kayser, Cristiane, Fathi, Nihal, García de la Peña Lefebvre, Paloma, Sibilia, Jean, Litinsky, Ira, Abignano, Giuseppina, Seskute, Goda, Saketkoo, Lesley Ann, Kerzberg, Eduardo, Bianchi, Washington, Castellví, Ivan, Limonta, Massimiliano, Rimar, Doron, Couto, Maura, Spertini, François, Marcoccia, Antonella, Kahl, Sarah, Hsu, Ivien M., Martin, Thierry, Moiseev, Sergey, Chung, Lorinda S., Schmeiser, Tim, Majewski, Dominik, Zdrojewski, Zbigniew, Martínez-Barrio, Julia, Bernardino, Vera, Sommerlatte, Sabine, Levy, Yair, Rezus, Elena, Nuri Pamuk, Omer, Sarzi Puttini, Piercarlo, Poormoghim, Hadi, Kötter, Ina, Gaches, Francis, Belloli, Laura, Sfikakis, Petros, Markus, Juliana, Feldman, Gary R, Ramazan, Ana-Maria, Scherer, H.U., Truchetet, Marie-Elise, Lescoat, Alain, Dagna, Lorenzo, van Laar, J.M., Rudnicka, Lidia, Oliveira, Susana, Atzeni, Fabiola, Kuwana, Masataka, Mekinian, Arsene, Martin, Mickaël, Tanaka, Yoshiya, Elhai, Muriel, Sritharan, Nanthara, Boubaya, Marouane, Balbir-Gurman, Alexandra, Siegert, Elise, Hachulla, Eric, de Vries-Bouwstra, Jeska, Riemekasten, Gabriela, Distler, Jörg H W, Rosato, Edoardo, Del Galdo, Francesco, Mendoza, Fabian A, Furst, Daniel E, de la Puente, Carlos, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Bloch-Queyrat, Coralie, and Allanore, Yannick

Published
2022
Full Text
View/download PDF

3. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study

Author

Aikawa, Nadia E, Kupa, Leonard V K, Pasoto, Sandra G, Medeiros-Ribeiro, Ana C, Yuki, Emily F N, Saad, Carla G S, Pedrosa, Tatiana, Fuller, Ricardo, Shinjo, Samuel K, Sampaio-Barros, Percival D, Andrade, Danieli C O, Pereira, Rosa M R, Seguro, Luciana P C, Valim, Juliana M L, Waridel, Filipe, Sartori, Ana Marli C, Duarte, Alberto J S, Antonangelo, Leila, Sabino, Ester C, Menezes, Paulo Rossi, Kallas, Esper G, Silva, Clovis A, and Bonfa, Eloisa

Published
2022
Full Text
View/download PDF

4. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

Author

Silva, Clovis A., Medeiros-Ribeiro, Ana C., Kupa, Leonard V. K., Yuki, Emily F. N., Pasoto, Sandra G., Saad, Carla G. S., Fusco, Solange R. G., Pereira, Rosa M. R., Shinjo, Samuel K., Halpern, Ari S. R., Borba, Eduardo F., Souza, Fernando H. C., Guedes, Lissiane K. N., Miossi, Renata, Bonfiglioli, Karina R., Domiciano, Diogo S., Shimabuco, Andrea Y., Andrade, Danieli C. O., Seguro, Luciana P. C., Fuller, Ricardo, Sampaio-Barros, Percival D., Assad, Ana P. L., Moraes, Julio C. B., Goldenstein-Schainberg, Claudia, Giardini, Henrique A. M., Silva, Henrique C., Martins, Victor A. O., Villamarin, Lorena E. B., Novellino, Renata S., Sales, Lucas P., Araújo, Carlo S. R., Silva, Matheus S. R., Filho, Dilson M. N., Lopes, Marta H., Duarte, Alberto J. S., Kallas, Esper G., Aikawa, Nadia E., and Bonfa, Eloisa

Published
2022
Full Text
View/download PDF

5. Long‐term follow‐up of anti‐infliximab antibodies in radiographic axial spondyloarthritis patients: a marker of drug survival and tapering

Author

Pimentel, Clarissa Q., primary, Medeiros‐Ribeiro, Ana Cristina, additional, Shimabuco, Andrea Y., additional, Sampaio‐Barros, Percival D., additional, Moraes, Júlio César B., additional, Schainberg, Claudia G., additional, Gonçalves, Celio Roberto, additional, Leon, Elaine P., additional, Kupa, Léonard De Vinci K., additional, Pasoto, Sandra G., additional, Aikawa, Nádia E., additional, Silva, Clovis A., additional, Bonfa, Eloisa, additional, and Saad, Carla G. S., additional

Published
2024
Full Text
View/download PDF

6. Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering.

Author

Pimentel, Clarissa Q., Medeiros‐Ribeiro, Ana Cristina, Shimabuco, Andrea Y., Sampaio‐Barros, Percival D., Moraes, Júlio César B., Schainberg, Claudia G., Gonçalves, Celio Roberto, Leon, Elaine P., Kupa, Léonard De Vinci K., Pasoto, Sandra G., Aikawa, Nádia E., Silva, Clovis A., Bonfa, Eloisa, and Saad, Carla G. S.

Subjects
ANTI-inflammatory agents, RESEARCH funding, ANKYLOSIS, DRUG therapy, METHOTREXATE, RETROSPECTIVE studies, DESCRIPTIVE statistics, DECISION making in clinical medicine, ANTIBODY formation, LONGITUDINAL method, DRUG efficacy, MEDICAL records, ACQUISITION of data, SPONDYLOARTHROPATHIES, INFLIXIMAB, GENERIC drug substitution, TREATMENT failure, CONFIDENCE intervals, BIOAVAILABILITY, PATIENT aftercare, BIOMARKERS, DRUG tolerance
Abstract

Objective: The aim of this study was to evaluate the influence of anti‐infliximab (IFX) antibodies on three different points of care: response/tolerance to IFX, tapering strategy, and in a subsequent treatment with a second tumor necrosis factor inhibitor (TNFi). Methods: A prospective cohort of 60 patients with radiographic axial spondyloarthritis who received IFX were evaluated retrospectively regarding clinical/laboratorial data, IFX levels, and anti‐IFX antibodies at baseline, after 6, 12 to 14, 22 to 24, 48 to 54, 96 to 102 weeks, and before tapering or switching. Results: Anti‐IFX antibodies were detected in 27 patients (45%), of whom 23 (85.1%) became positive in the first year of IFX treatment. In comparison to the group that was negative for anti‐IFX antibodies, patients who were positive for anti‐IFX antibodies demonstrated the following: less use of methotrexate as a concomitant treatment to IFX (5 [18.5%] vs 14 [42.4%]; P = 0.048), more infusion reactions at 22 to 24 weeks (P = 0.020) and 48 to 54 weeks (P = 0.034), more treatment failures (P = 0.028) at 48 to 54 weeks, reduced overall IFX survival (P < 0.001), and lower sustained responses (P = 0.044). Of note, patients who were positive for anti‐IFX antibodies exhibited a shorter tapering survival (9.9 months [95% confidence interval (CI) 4.0–15.8] vs 63.4 months [95% CI 27.9–98.8]; P = 0.004) in comparison with patients who were negative for anti‐IFX antibodies. Conversely, for patients who failed IFX, patients who were positive for anti‐IFX antibodies had better clinical response to the second TNFi at three months (15 [83.3%] vs 3 [27.3%]; P = 0.005) and six months (15 [83.3%] vs 4 [36.4%]; P = 0.017) than the patients who were negative for anti‐IFX antibodies after switching. Conclusion: This study provided novel data that anti‐IFX antibodies is a parameter for reduced tapering survival, reinforcing its detection to guide clinical decision. Additionally, we confirmed in a long‐term cohort the anti‐IFX antibody association with worse IFX performance and as predictor of the second TNFi good clinical response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

Author

Elhai, Muriel, primary, Sritharan, Nanthara, additional, Boubaya, Marouane, additional, Balbir-Gurman, Alexandra, additional, Siegert, Elise, additional, Hachulla, Eric, additional, de Vries-Bouwstra, Jeska, additional, Riemekasten, Gabriela, additional, Distler, Jörg H W, additional, Rosato, Edoardo, additional, Del Galdo, Francesco, additional, Mendoza, Fabian A, additional, Furst, Daniel E, additional, de la Puente, Carlos, additional, Hoffmann-Vold, Anna-Maria, additional, Gabrielli, Armando, additional, Distler, Oliver, additional, Bloch-Queyrat, Coralie, additional, Allanore, Yannick, additional, Matucci Cerinic, Marco, additional, Walker, Ulrich, additional, Iannone, Florenzo, additional, Jordan, Suzana, additional, Becvar, Radim, additional, Kowal Bielecka, Otylia, additional, Cutolo, Maurizio, additional, Cuomo, Giovanna, additional, Kedor, Claudia, additional, Rednic, Simona, additional, Avouac, Jérome, additional, Vlachoyiannopoulos, P., additional, Montecucco, C., additional, Stork, Jiri, additional, Inanc, Murat, additional, Carreira, Patricia E., additional, Novak, Srdan, additional, Czirják, László, additional, Iudici, Michele, additional, Kucharz, Eugene J., additional, Zanatta, Elisabetta, additional, Perdan-Pirkmajer, Katja, additional, Coleiro, Bernard, additional, Moroncini, Gianluca, additional, Farge Bancel, Dominique, additional, Airò, Paolo, additional, Hesselstrand, Roger, additional, Radic, Mislav, additional, Braun-Moscovici, Yolanda, additional, Lo Monaco, Andrea, additional, Hunzelmann, Nicolas, additional, Pellerito, Raffaele, additional, Giollo, Alessandro, additional, Morovic-Vergles, Jadranka, additional, Denton, Christopher, additional, Vonk, Madelon, additional, Damjanov, Nemanja, additional, Henes, Jörg, additional, Ortiz Santamaria, Vera, additional, Heitmann, Stefan, additional, Krasowska, Dorota, additional, Hasler, Paul, additional, Kohm, Michaela, additional, Foeldvari, Ivan, additional, Bajocchi, Gianluigi, additional, Salvador, Maria João, additional, Stamenkovic, Bojana, additional, Selmi, Carlo Francesco, additional, Tikly, Mohammed, additional, Ananieva, Lidia P., additional, Herrick, Ariane, additional, Müller-Ladner, Ulf, additional, De Palma, Raffaele, additional, Engelhart, Merete, additional, Szücs, Gabriela, additional, Sobrino Grande, Cristina, additional, Midtvedt, Øyvind, additional, Launay, David, additional, Riccieri, Valeria, additional, Ionescu, Ruxandra Maria, additional, Sha, Ami, additional, Gheorghiu, Ana Maria, additional, Sunderkötter, Cord, additional, Ingegnoli, Francesca, additional, Mouthon, Luc, additional, Smith, Vanessa, additional, Cantatore, Francesco Paolo, additional, Ullman, Susanne, additional, Alberto von Mühlen, Carlos, additional, Pozzi, Maria Rosa, additional, Eyerich, Kilian, additional, Wiland, Piotr, additional, Vanthuyne, Marie, additional, Alegre-Sancho, Juan Jose, additional, Herrmann, Kristine, additional, De Langhe, Ellen, additional, Anic, Branimir, additional, Üprus, Maria, additional, Yavuz, Sule, additional, Granel, Brigitte, additional, de Souza Müller, Carolina, additional, Busquets, Joanna, additional, Agachi, Svetlana, additional, Stebbings, Simon, additional, Mathieu, D'Alessandro, additional, Sampaio-Barros, Percival D., additional, Stamp, Lisa, additional, Solanki, Kamal, additional, Veale, Douglas, additional, Loyo, Esthela, additional, Li, Mengtao, additional, Abdel Atty Mohamed, Walid Ahmed, additional, Gigante, Antonietta, additional, Oksel, Fahrettin, additional, Tanaseanu, Cristina-Mihaela, additional, Foti, Rosario, additional, Ancuta, Codrina, additional, Maurer, Britta, additional, van Laar, Jacob, additional, Kayser, Cristiane, additional, Fathi, Nihal, additional, García de la Peña Lefebvre, Paloma, additional, Sibilia, Jean, additional, Litinsky, Ira, additional, Abignano, Giuseppina, additional, Seskute, Goda, additional, Saketkoo, Lesley Ann, additional, Kerzberg, Eduardo, additional, Bianchi, Washington, additional, Castellví, Ivan, additional, Limonta, Massimiliano, additional, Rimar, Doron, additional, Couto, Maura, additional, Spertini, François, additional, Marcoccia, Antonella, additional, Kahl, Sarah, additional, Hsu, Ivien M., additional, Martin, Thierry, additional, Moiseev, Sergey, additional, Chung, Lorinda S., additional, Schmeiser, Tim, additional, Majewski, Dominik, additional, Zdrojewski, Zbigniew, additional, Martínez-Barrio, Julia, additional, Bernardino, Vera, additional, Sommerlatte, Sabine, additional, Levy, Yair, additional, Rezus, Elena, additional, Nuri Pamuk, Omer, additional, Sarzi Puttini, Piercarlo, additional, Poormoghim, Hadi, additional, Kötter, Ina, additional, Gaches, Francis, additional, Belloli, Laura, additional, Sfikakis, Petros, additional, Markus, Juliana, additional, Feldman, Gary R, additional, Ramazan, Ana-Maria, additional, Scherer, H.U., additional, Truchetet, Marie-Elise, additional, Lescoat, Alain, additional, Dagna, Lorenzo, additional, van Laar, J.M., additional, Rudnicka, Lidia, additional, Oliveira, Susana, additional, Atzeni, Fabiola, additional, Kuwana, Masataka, additional, Mekinian, Arsene, additional, Martin, Mickaël, additional, and Tanaka, Yoshiya, additional

Published
2022
Full Text
View/download PDF

9. Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis

Author

Fernández-Ávila, Daniel G., Bautista-Molano, Wilson, Brance, María Lorena, Ávila Pedretti, María Gabriela, Vargas, Rubén Burgos, Díaz Coto, José Francisco, Gutiérrez, Luis Arturo, Gutiérrez, Marwin, Ho, Enrique Giraldo, Ibáñez Vodnizza, Sebastián Eduardo, Jáuregui, Edwin, Ocampo, Vanessa, Palominos, Penélope Esther, Palleiro Rivero, Daniel Ruben, Quiceno, Guillermo Andrés, Sommerfleck, Fernando Andrés, Vega Espinoza, Luis Enrique, Hinojosa, Oscar Vega, Barrezueta, Claudia Vera, Corbacho, Inés, Cosentino, Vanesa Laura, Sariego, Annelise Goecke, Resende, Gustavo Gomes, Saldarriaga-Rivera, Lina María, Pacheco Tena, Cesar Francisco, Citera, Gustavo, Lozada, Carlos, Ranza, Roberto, Sampaio-Barros, Percival D., Schneeberger, Emilce, and Soriano, Enrique R.

Abstract

ObjectivePsoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective was to generate evidence-based recommendations on the management of PsA in Pan American League of Associations for Rheumatology (PANLAR) countries.MethodsWe used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to adapt the 2019 recommendations of the European Alliance of Associations for Rheumatology. A working group consisting of rheumatologists from various countries in Latin America identified relevant topics for the treatment of PsA in the region. The methodology team updated the evidence and synthesized the information used to generate the final recommendations. These were then discussed and defined by a panel of 31 rheumatologists from 15 countries.ResultsTheses guidelines report 15 recommendations addressing therapeutic targets, use of antiinflammatory agents and corticosteroids, treatment with disease-modifying antirheumatic drugs (conventional synthetic, biologic, and targeted synthetic), therapeutic failure, optimization of biologic therapy, nonpharmacological interventions, assessment tools, and follow-up of patients with PsA.ConclusionHere we present a set of recommendations to guide decision making in the treatment of PsA in Latin America, based on the best evidence available, considering resources, medical expertise, and the patient’s values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, healthcare settings in each country, and a tailored evaluation of patients.

Published
2024
Full Text
View/download PDF

10. Collagen V α1 Chain Decrease in Papillary Dermis from Early Systemic Sclerosis: A New Proposal in Cutaneous Fibrosis Molecular Structure

Author

de Morais, Jymenez, primary, Velosa, Ana Paula P., additional, Andrade, Priscila C., additional, Frediani, Denise, additional, Carrasco, Solange, additional, Queiroz, Zelita A. de Jesus, additional, Martin, Patrícia, additional, Saito, Renata F., additional, Elias, Vitória, additional, Goldenstein-Schainberg, Cláudia, additional, Chammas, Roger, additional, Sampaio-Barros, Percival D., additional, Capelozzi, Vera L., additional, and Teodoro, Walcy R., additional

Published
2022
Full Text
View/download PDF

13. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine

Author

Aikawa, Nadia E, primary, Kupa, Leonard V K, additional, Silva, Clovis A, additional, Saad, Carla G S, additional, Pasoto, Sandra G, additional, Yuki, Emily F N, additional, Fusco, Solange R G, additional, Shinjo, Samuel K, additional, Andrade, Danieli C O, additional, Sampaio-Barros, Percival D, additional, Pereira, Rosa M R, additional, Chasin, Anna C S, additional, Shimabuco, Andrea Y, additional, Luppino-Assad, Ana P, additional, Leon, Elaine P, additional, Lopes, Marta H, additional, Antonangelo, Leila, additional, Medeiros-Ribeiro, Ana C, additional, and Bonfa, Eloisa, additional

Published
2022
Full Text
View/download PDF

14. Effect of an Exercise Bout Prior to the Booster Dose of an Inactivated SARS-CoV-2 Vaccine on Immunogenicity in Immunocompromised Patients

Author

Gualano, Bruno, primary, Saad, Carla Golçalves S., additional, Sieczkowska, Sofia Mendes, additional, Lemes, Italo Ribeiro, additional, da Silva, Rafael Pires, additional, Pinto, Ana J., additional, Mazzolani, Bruna C., additional, Smaira, Fabiana I, additional, Gil, Saulo, additional, de Oliveira Júnior, Gersiel Nascimento, additional, Aikawa, Nadia Emi, additional, Ribeiro, Ana Cristina Medeiros, additional, Silva, Clovis Artur, additional, Yuki, Emily F. N., additional, Pasoto, Sandra G., additional, Rodrigues Pereira, Rosa Maria, additional, Shinjo, Samuel K, additional, de Andrade, Danieli Castro Oliveira, additional, Sampaio-Barros, Percival D., additional, Roschel, Hamilton, additional, and Bonfa, Eloisa, additional

Published
2022
Full Text
View/download PDF

16. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.

Author

Aikawa, Nadia E, Kupa, Leonard V K, Silva, Clovis A, Saad, Carla G S, Pasoto, Sandra G, Yuki, Emily F N, Fusco, Solange R G, Shinjo, Samuel K, Andrade, Danieli C O, Sampaio-Barros, Percival D, Pereira, Rosa M R, Chasin, Anna C S, Shimabuco, Andrea Y, Luppino-Assad, Ana P, Leon, Elaine P, Lopes, Marta H, Antonangelo, Leila, Medeiros-Ribeiro, Ana C, and Bonfa, Eloisa

Subjects
RITUXIMAB, HUMAN research subjects, IMMUNOGLOBULINS, CONFIDENCE intervals, COVID-19 vaccines, MULTIPLE regression analysis, MULTIVARIATE analysis, AUTOIMMUNE diseases, FISHER exact test, MANN Whitney U Test, VACCINE effectiveness, INFORMED consent (Medical law), T-test (Statistics), MESSENGER RNA, DESCRIPTIVE statistics, RESEARCH funding, RHEUMATISM, PREDNISONE, DATA analysis, ODDS ratio, DATA analysis software
Abstract

Objectives To assess immunogenicity of a heterologous fourth dose of an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated vaccine (Sinovac-CoronaVac). Methods A total of 164 ARD patients who were coronavirus disease 2019 (COVID-19) poor/non-responders (negative anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies—NAb) to the third dose of Sinovac-CoronaVac received an additional heterologous dose of mRNA (BNT162b2) 3 months after last dose. IgG and NAb were evaluated before and after the fourth dose. Results Significant increases were observed after the fourth dose in IgG (66.4 vs 95.1%, P  < 0.001), NAb positivity (5.5 vs 83.5%, P  < 0.001) and geometric mean titre (29.5 vs 215.8 AU/ml, P  < 0.001), and 28 (17.1%) remained poor/non-responders. Patients with negative IgG after a fourth dose were more frequently under rituximab (P  = 0.001). Negative NAb was associated with older age (P  = 0.015), RA (P  = 0.002), SSc (P  = 0.026), LEF (P  = 0.016) and rituximab use (P  = 0.007). In multiple logistic regression analysis, prednisone dose ≥7.5 mg/day (OR = 0.34; P  = 0.047), LEF (OR = 0.32, P  = 0.036) and rituximab use (OR = 0.19, P  = 0.022) were independently associated with negative NAb after the fourth vaccine dose. Conclusions This is the largest study to provide evidence of a remarkable humoral response after the fourth dose of heterologous mRNA SARS-CoV-2 vaccination in ARD patients with poor/non-response to the third dose of an inactivated vaccine. We further identified that treatment, particularly rituximab and prednisone, impaired antibody response to this additional dose. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov , CoronavRheum #NCT04754698. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Symptomatic fractures in systemic sclerosis: A case–control study

Author

Sampaio-Barros, Marília M, Bortoluzzo, Adriana B, da Silva, Henrique Carriço, Luppino-Assad, Ana Paula, Pereira, Rosa Maria R, and Sampaio-Barros, Percival D

Abstract

This case–control study analyzed risk factors for symptomatic fractures in a group of 52 patients with systemic sclerosis compared with a group of 104 patients without fractures, matched for sex and age, who were attended at a single systemic sclerosis outpatient clinic from 2010 to 2020. Fractures affected predominantly vertebral (65.4%), rib (13.5%), and hip (7.7%) joints, while the mean age of fracture was 55.3 ± 9.5 years. Age at disease onset, age at diagnosis, disease duration, age at menarche, and age at menopause were similar in both groups, and 58.9% of the patients were menopausal at the time of the fracture. The presence of fractures had a significant association with densitometric osteoporosis (p < 0.001), lower weight (p = 0.032), and bone mineral index (p = 0.044), anti-RNA polymerase III (p = 0.040), use of corticosteroids (p = 0.019), and bisphosphonates (p < 0.001), as well as with densitometric T-scores of lumbar spine (p < 0.001), femoral neck (p = 0.025), and total hip (p = 0.013). Multivariate analysis showed that the variables significantly associated with fractures were high doses of corticosteroids (odds ratio = 4.10; 95% confidence interval = 1.290–13.090; p = 0.017), bisphosphonates (odds ratio = 3.91; 95% confidence interval = 1.699–8.984; p = 0.001), negative anti-Scl70 (OR = 0.34; 95% confidence interval = 0.124–0.943; p = 0.038), and lumbar T-score (odds ratio = 0.39; 95% confidence interval = 0.034–0.460; p = 0.010). In conclusion, symptomatic fractures were associated predominantly with lower bone mineral density of lumbar spine and use of high doses of corticosteroids and bisphosphonates in this cohort.

Published
2023
Full Text
View/download PDF

18. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients.

Author

Gualano, Bruno, Saad, Carla G. S., Sieczkowska, Sofia M., Lemes, Ítalo Ribeiro, Silva, Rafael Pires da, Pinto, Ana J., Mazzolani, Bruna C., Smaira, Fabiana I., Gil, Saulo, Oliveira-Junior, Gersiel, Aikawa, Nadia E., Medeiros-Ribeiro, Ana C., Silva, Clovis A., Yuki, Emily F. N., Pasoto, Sandra G., Pereira, Rosa Maria R., Shinjo, Samuel K., Andrade, Danieli C. O., Sampaio-Barros, Percival D., and Roschel, Hamilton

Subjects
COVID-19 vaccines, BOOSTER vaccines, IMMUNE response, IMMUNOCOMPROMISED patients, SPONDYLOARTHROPATHIES
Abstract

This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results